- Home
- VET vs MDXG Comparison
VET vs MDXG Comparison
Compare VET & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VET
- MDXG
- Stock Information
- Founded
- VET 1994
- MDXG 2006
- Country
- VET Canada
- MDXG United States
- Employees
- VET N/A
- MDXG N/A
- Industry
- VET Oil & Gas Production
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- VET Energy
- MDXG Health Care
- Exchange
- VET Nasdaq
- MDXG Nasdaq
- Market Cap
- VET 961.0M
- MDXG 877.4M
- IPO Year
- VET N/A
- MDXG N/A
- Fundamental
- Price
- VET $7.53
- MDXG $6.34
- Analyst Decision
- VET
- MDXG Strong Buy
- Analyst Count
- VET 0
- MDXG 2
- Target Price
- VET N/A
- MDXG $12.50
- AVG Volume (30 Days)
- VET 1.5M
- MDXG 628.7K
- Earning Date
- VET 07-30-2025
- MDXG 07-30-2025
- Dividend Yield
- VET 4.78%
- MDXG N/A
- EPS Growth
- VET N/A
- MDXG N/A
- EPS
- VET N/A
- MDXG 0.27
- Revenue
- VET $1,296,504,678.00
- MDXG $352,375,000.00
- Revenue This Year
- VET $39.62
- MDXG $9.55
- Revenue Next Year
- VET N/A
- MDXG $11.43
- P/E Ratio
- VET N/A
- MDXG $23.48
- Revenue Growth
- VET 3.24
- MDXG 5.34
- 52 Week Low
- VET $5.14
- MDXG $5.47
- 52 Week High
- VET $11.48
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- VET 52.40
- MDXG 53.33
- Support Level
- VET $7.19
- MDXG $5.86
- Resistance Level
- VET $7.55
- MDXG $6.42
- Average True Range (ATR)
- VET 0.25
- MDXG 0.21
- MACD
- VET -0.07
- MDXG 0.07
- Stochastic Oscillator
- VET 26.67
- MDXG 87.30
About VET Vermilion Energy Inc. Common (Canada)
Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, development, and optimization of producing properties in North America, Europe, and Australia. The majority of Vermilion's revenue is derived from the production and sale of petroleum and natural gas. In each market, the company relies on a host of drilling and well-completion techniques to keep production at attractive levels. Geographically, the company derives majority of its revenue from Canada.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.